Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16679673 | 0.78 | TNF (0.47) | TNFMEN1KMT2APDE4APDE4B | |
| SCHEMBL16692506 | 0.77 | TNF (0.50) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12497365 | 0.77 | TNF (0.43) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19053750 | 0.76 | TNF (0.44) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16680070 | 0.75 | MEN1 (0.47) | MEN1KMT2AKDM4E | |
| SCHEMBL28076631 | 0.75 | TNF (0.55) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16680515 | 0.74 | GBA1 (0.53) | MEN1KMT2AKDM4ECYP3A4CYP2D6 | |
| SCHEMBL6682844 | 0.74 | TNF (0.44) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9774274 | 0.72 | HDAC7 (0.39) | TNFMEN1KMT2APDE4APDE4B | |
| SCHEMBL10318765 | 0.72 | UTS2R (0.53) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885MEN1 3963/4885KMT2A 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.